PG16: Leiomyomata: Clinical Updates, Research Developments And Disparities In Disease, Outcomes And Access To Care

Date:October 13, 2013

Time:8:15 am - 5:00 pm

Location:Room 251 - Boston Convention and Exhibition Center


Gloria Richard-Davis, M.D. (Chair ), University of Arkansas Medical Sciences

Ayman Al-Hendy, M.D., Ph.D. (Co-Chair ), Meharry Medical College

Donna Baird, Ph.D., National Institute of Environmental Health Services (NIEHS)

James H. Segars, M.D., National Institute of Health (NIH)


Developed in Cooperation with the Fibroid Special Interest Group and the Health Disparities Special Interest Group

Patient care

Uterine leiomyomata (fibroids), benign estrogen-dependent tumors of the uterine wall, are a common cause of acute and chronic pelvic pain in women. Uterine fibroids affect 40-80% of women of reproductive age and are the leading indication for hysterectomy in African-American women. More than 600,000 hysterectomies were done in the United States in 2000 because of leiomyomata. At a mean cost of $8 billion per year, African-American women are particularly affected as the prevalence of uterine fibroids is about three times higher in that ethnic group compared with Caucasians. Currently there is no effective medical treatment for this common disease, and the impact of uterine fibroids on fertility remains controversial. Treatment options for the management of fibroids have largely focused on surgical options with few focusing on reproductive-sparing procedures. Healthcare providers show no agreement on the best management option, partially because of their lack of current evidence-based knowledge (including the cause), of uterine fibroids. This live course, designed for gynecologists, will provide a clear and meaningful overview of the problem, discuss current fibroid treatment options and their effect on fertility, and probe the future of these treatments.

At the conclusion of this course, participants should be able to: 

  1. Explain the developmental origin of uterine fibroids.
  2. Describe non-surgical, reproductive-sparing approach for treatment of uterine leiomyomata.
  3. Summarize the scientific data on why uterine leiomyomata are more common in African Americans.
  4. Discuss the role of myomectomy in the outcomes of assisted reproductive technologies.


View Details
Learn More | Join | Renew
Back to Top